Substituted nucleosides, nucleotides and analogs thereof
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof,
having the structure:
wherein:
B 1 is selected from the group consisting of
R 1 is selected from the group consisting of an unsubstituted C 1-6 alkyl and an unsubstituted C 2-6 alkynyl;
each -------- is absent;
R 2 is fluoro;
R P is absent;
R 3 is —OH;
R 4 is hydrogen or
R 5A is selected from the group consisting of OH,
R 5B is selected from the group consisting of an OH, —O-unsubstituted phenyl, —O— unsubstituted naphthyl,
R 6C is selected from the group consisting of hydrogen and an unsubstituted C 1-6 alkyl;
R 6F is NHR 6I ;
R 6I is hydrogen;
R 11A , R 12A , R 11B and R 12B are each hydrogen;
R 13 is selected from the group consisting of an unsubstituted C 1-6 alkyl and an unsubstituted C 3-6 cycloalkyl;
R 14 and R 15 are each independently selected from the group consisting of hydrogen and an unsubstituted C 1-6 alkyl;
R 13A and R 13B are each an unsubstituted —O-C 1-4 alkyl;
n is 0 or 1;
R 9 , R 10 and R 11 are each hydrogen; and
Z 1 , Z 1A and Z 1B are each O.
2. The compound of claim 1 having the structure
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 having the structure
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 having the structure
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 having the structure
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 having the structure
or a pharmaceutically acceptable salt thereof.